Jasper Therapeutics Inc   (JSPR)
Other Ticker:  
Price: $23.0200 $0.18 0.788%
Day's High: $23.695 Week Perf: 10.89 %
Day's Low: $ 22.58 30 Day Perf: -0.82 %
Volume (M): 66 52 Wk High: $ 31.01
Volume (M$): $ 1,513 52 Wk Avg: $14.06
Open: $22.80 52 Wk Low: $4.00

 Market Capitalization (Millions $) 253
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) 53
 Capital Exp. (TTM) (Millions $) 0

Jasper Therapeutics Inc
Jasper Therapeutics Inc is a biotechnology company specializing in the development of cell-based therapies for various diseases. They focus on the use of hematopoietic stem cells (HSCs) to treat cancer, autoimmune disorders, and other genetic diseases. Their innovative approach involves the use of engineered HSCs to improve patient outcomes and reduce the need for traditional transplantation methods. The company aims to revolutionize the field of stem cell therapy by providing safer, more effective treatment options for patients in need.

   Company Address: 2200 Bridge Pkwy Redwood City 94065 CA
   Company Phone Number: 549-1400   Stock Exchange / Ticker: NASDAQ JSPR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Jasper Therapeutics Advancing Briquilimab in the Treatment of Urticaria: An Analysis of Recent Developments

Published Tue, Mar 19 2024 12:01 PM UTC

Jasper Therapeutics, a biotechnology company specializing in the development of briquilimab, a unique antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases, has made significant progress in its research. Recent announcements regarding the dosing of the first patient in the Phase 1b/2a SPOTLIGHT Clinical Study and the presentation of preclinical briquilimab da...

Clinical Study

Positive Results Show Briquilimab's Potential as a Novel Therapy for Fanconi Anemia and Mast Cell Driven Diseases

Published Fri, Mar 15 2024 12:00 PM UTC

Utilizing groundbreaking research and innovative techniques, Jasper Therapeutics, a leading biotechnology company, has recently unveiled positive data on the effectiveness of briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA). This breakthrough represents a significant step forward in the development of targeted therapies for a range of diseases, pa...

Clinical Study

Jasper Therapeutics Presents Promising Preclinical Data on Briquilimab, Targeting Mast Cell-Driven Diseases, at AAAAI Annual Meeting

Published Fri, Feb 23 2024 1:01 PM UTC

Jasper Therapeutics Unveils Promising Preclinical Data on Briquilimab at AAAAI Annual MeetingREDWOOD CITY, Calif., Feb. 23, 2024 - Jasper Therapeutics, a leading biotechnology company specializing in the development of briquilimab, an innovative antibody therapy for mast cell driven diseases like chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), pr...

Financing Agreement

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock, Aims to Enhance Treatment Approaches for Mast-Cell Driven Diseases

Published Tue, Feb 6 2024 2:00 PM UTC

Jasper Therapeutics to Raise $50 Million in Common Stock Offering for Advancement of Mast-Cell Driven Disease Treatments
REDWOOD CITY, Calif., Feb. 06, 2024 - Jasper Therapeutics, a clinical-stage biotechnology company dedicated to developing innovative antibody therapies, has recently disclosed its plans to invest the considerable sum of $50 million in advancing its pre...

Clinical Study

Promising Preclinical Data for Briquilimab Presented at AAAAI 2024 Annual Meeting: A Potential Breakthrough in Treating Mast Cell Driven Diseases and Myelodysplastic Syndromes

Published Mon, Feb 5 2024 1:01 PM UTC

Abstract:This article highlights the recent preclinical data presentations of briquilimab, a novel antibody therapy developed by Jasper Therapeutics, Inc. The data were presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 Annual Meeting. The article aims to outline the facts presented in the research, focusing on the potential of briquilimab in ...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com